Industry Insight
Discovery Technology
Analytical Laboratory Technology
Biopharma
Manufacturing
Delivery Systems
Ingredients, Formulation and Finishing
Bioprocessing
View our other publications with free access to extensive archives
  To print this article:
Existing subscribers please log in:
 
  USER NAME  
  PASSWORD  
   Or select

Or become a subscriber
 
 
 

Reducing Attrition Rates in Anticancer Drug Development

Attrition rates in the clinical phases of anticancer drug development are unacceptably high. Pam Barnacal interviews Jon Waterman-Smith of PRECOS about why this is and what can be done to predict the potential effi cacy/toxicity of new anticancer drugs before they enter the clinic.

Jon Waterman-Smith of PRECOS (December 2011)

    View full article    |    Back to Discovery Technology section




Advair,Flovent,VentolinSymbicort,Serevent,FlonaseAstelin Rhinocort
IPTonline © 2004 The Pharmaceutical Technology Journal | Terms and Conditions | info@iptonline.com | UK Contacts |
Providing a platform of communication on new ideas, developments and innovations | UK Tel No. +44 20 77243456 | Back to top of page |